Акамол тева цена инструкция по применению

Медикамент запрещен для реализации в аптеках.

Международное непатентованное название ? Парацетамол

Активное вещество — парацетамол.

Анальгетики-антипиретики — производные пара-аминофенола

Показания к применению Акамол-Тева таблетки 500мг Боли слабой и умеренной интенсивности (головная и зубная боль, мигрень, боль в спине, артралгия, миалгия, невралгия, меналгия), лихорадочный синдром при простудных заболеваниях.

Противопоказания Акамол-Тева таблетки 500мг Гиперчувствительность, нарушение функций почек и печени, алкоголизм, детский возраст (до 6 лет).

Фармакологическое действие Анальгезирующее, жаропонижающее. Ингибирует синтез простагландина и снижает возбудимость центра терморегуляции гипоталамуса. Быстро всасывается из ЖКТ, связывается с белками плазмы. Период полувыведения из плазмы 1-4 ч. Метаболизируется в печени с образованием глюкуронида и сульфата парацетамола. Выводится почками главным образом в виде продуктов конъюгации, менее 5% экскретируется в неизмененном виде.

Побочное действие Акамол-Тева таблетки 500мг Агранулоцитоз, тромбоцитопения, анемия, почечная колика, асептическая пиурия, интерстициальный гломерулонефрит, аллергические реакции в виде кожных высыпаний.

Передозировка Симптомы: в первые 24 ч — бледность, тошнота, рвота и боль в абдоминальной области; через 12-48 ч — повреждения почек и печени с развитием печеночной недостаточности (энцефалопатия, кома, летальный исход), сердечные аритмии и панкреатит. Поражение печени возможны при приеме 10 г и более (у взрослых).Лечение: назначение метионина внутрь или в/в введение N-ацетилцистеина.

Взаимодействие Акамол-Тева таблетки 500мг Увеличивает эффект непрямых антикоагулянтов (производных кумарина) и вероятность поражения печени гепатотоксичными препаратами. Метоклопрамид повышает, а холестирамин снижает скорость всасывания. Барбитураты уменьшают жаропонижающую активность.

Особые указания Риск передозировки возрастает у больных с алкогольными заболеваниями печени нецирротического характера.При приеме препарата Цефекон Д с осторожностью применять при синдроме Жильбера. Длительное применение одновременно с антикоагулянтами непрямого действия требует постоянного врачебного контроля.

Условия хранения Хранить при комнатной температуре, в сухом прохладном месте.

Информация о лекарственных препаратах, размещенная на AptekaMos.ru, не должна использоваться неспециалистами для самостоятельного принятия решения об их покупке и применении без консультации врача.
Свидетельство о регистрации средства массовой информации ЭЛ № ФС77-44705 выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор) 21 апреля 2011 года.

Список взаимодействия ЛС:

Top 20 medicines with the same components:

Top 20 medicines with the same treatments:

Adults, the elderly and young persons 16 years and over:

2 tablets every 4 hours to a maximum of 8 tablets in 24 hours.

Children 6 — 9 years:

½ tablet every 4 hours to a maximum of 4 doses in 24 hours.

Children 10 — 11 years:

1 tablet every 4 hours to a maximum of 4 doses in 24 hours

Adolescents 12 — 15 years:

1 to 1 ½ tablets every 4 hours to a maximum of 4 doses in 24 hours

Do not give to children aged under 6 years of age.

Care is advised in the administration of Acamol-Teva to patients with severe renal or severe hepatic impairment. The hazards of overdose are greater in those with non-cirrhotic alcoholic liver disease.

Do not take more medicine than the label tells you to. If you do not get better, talk to your doctor.

Contains Acamol-Teva.

Do not take anything else containing Acamol-Teva while taking this medicine.

Talk to your doctor at once if you take too much of this medicine, even if you feel well. This is because too much Acamol-Teva can cause delayed, serious liver damage.

Patients should be advised that Acamol-Teva may cause severe skin reactions. If a skin reaction such as skin reddening, blisters, or rash occurs, they should stop use and seek medical assistance right away.

Adverse effects of Acamol-Teva are rare. Very rare cases of serious skin reactions have been reported. There have been reports of blood dyscrasias including thrombocytopenia purpura, methaemoglobenaemia and agranulocytosis, but these were not necessarily causality related to Acamol-Teva.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Liver damage is possible in adults who have taken 10g or more of Acamol-Teva. Ingestion of 5g or more of Acamol-Teva may lead to liver damage if the patient has risk factors (see below).

Risk Factors

If the patient

a) Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John’s Wort or other drugs that induce liver enzymes.

Or

b) Regularly consumes ethanol in excess of recommended amounts.

Or

c) Is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms

Symptoms of Acamol-Teva overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.

Management

Immediate treatment is essential in the management of Acamol-Teva overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines, see BNF overdose section.

Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma Acamol-Teva concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable).

Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of Acamol-Teva however, the maximum protective effect is obtained up to 8 hours post ingestion.

If required the patient should be given intravenous-N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital.

Management of patients who present with serious hepatic dysfunction beyond 24 hours from ingestion should be discussed with the NPIS or a liver unit.

Mechanisms of Action/Effect

Analgesic — the mechanism of analgesic action has not been fully determined. Acamol-Teva may act predominantly by inhibiting prostaglandin synthesis in the central nervous system (CNS) and to a lesser extent, through a peripheral action by blocking pain-impulse generation.

The peripheral action may also be due to inhibition of prostaglandin synthesis or to inhibition of the synthesis or actions of other substances that sensitise pain receptors to mechanical or chemical stimulation.

Antipyretic — Acamol-Teva probably produces antipyresis by acting centrally on the hypothalamic heat-regulation centre to produce peripheral vasodilation resulting in increased blood flow through the skin, sweating and heat loss. The central action probably involves inhibition of prostaglandin synthesis in the hypothalamus.

Absorption and Fate

Acamol-Teva is readily absorbed from the gastro-intestinal tract with peak plasma concentrations occurring about 30 minutes to 2 hours after ingestion. It is metabolised in the liver and excreted in the urine mainly as the glucuronide and sulfate conjugates. Less than 5% is excreted as unchanged Acamol-Teva. The elimination half-life varies from about 1 to 4 hours. Plasma-protein binding is negligible at usual therapeutic concentrations but increases with increasing concentrations.

A minor hydroxylated metabolite which is usually produced in very small amounts by mixed-function oxidases in the liver and which is usually detoxified by conjugation with liver glutathione may accumulate following Acamol-Teva overdosage and cause liver damage.

• The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review

• Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

• Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies

• Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache

• Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction stu

• Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L_Rx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

• Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches 5% and Lidocaine Medicated Plaster 5% in Healthy Subjects

• The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder

• Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic

• Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

• β-arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation

• Machine learning approach to predict medication overuse in migraine patients

• Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia

• Lidocaine as an element of multimodal analgesic therapy in major spine surgical procedures in children: a prospective, randomized, double-blind study

• Comparison of healthcare resource utilization and costs amongpatients with migraine with potentially adequate and insufficient triptanresponse

• An Evidence-Based Review of Fremanezumab for the Treatment of Migraine

• G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial)

• Lidocaine Reduces Sevoflurane Consumption and Improves Recovery Profile in Children Undergoing Major Spine Surgery

• Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone

• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

References:

• https://www.drugs.com/search.php?searchterm=acamol-teva
• https://pubmed.ncbi.nlm.nih.gov/?term=acamol-teva

Available in countries

Find in a country: